SGXTAPI@EC2610A

PUXING ENERGY

STARCOIN GROUP

KNOWLEDGE ATLAS

EASY SMART GP

WORLD SUPER

XL2CSOPSMSN-U

PPS INT'L

LAP KEI ENGRG

CHINA FORTUNE

XL2CSOPSMSN

02228

XTALPI Limited (stock code: 2228) released its financial report for the period ending December 31, 2025, expecting revenue to reach 800 million yuan in 2025, a year-on-year increase of 201%. Among them, revenue from drug discovery solutions is expected to be 538 million yuan, an increase of 418.9%; revenue from AI for Science smart solutions is expected to be 265 million yuan, an increase of 62.6%. Operating profit is expected to be 55.24 million yuan, a significant improvement compared to a loss of 684 million yuan in the same period last year. The company completed the issuance of zero-coupon convertible bonds worth HKD 2.866 billion on January 28, 2026

雷帝触网

XTALPI

XTALPI expects revenue of 800 million in 2025: operating profit of 55.24 million, just issued HKD 2.9 billion bonds

159837

159849

516930

516500

Hong Kong-listed "AI drug discovery star company" XTALPI has delivered its first report of turning losses into profits since its listing. In 2025, XTALPI achieved revenue of 8

- Crystal Holding, an "AI pharmaceutical star" in Hong Kong, reported a significant turnaround in 2025 with a revenue of 802 million CNY, a 201.2% increase year-on-year, and a net profit of 124 million CNY, reversing a loss of 1.517 billion CNY in 2024.  
- The primary driver of revenue was the core business segment "drug discovery solutions," which generated 538 million CNY—an astonishing 418.9% growth—mainly due to a key collaboration with DoveTree in multiple drug development projects.  
- Crystal Holding also benefitted from other income, totaling 514 million CNY, significantly impacting profitability and easing the burden of prior financial losses.

Wallstreetcn

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

ChinaAMC CSI Biotechnology Theme ETF

The Reality and Illusion of "AI Drug Discovery" XTALPI's Turnaround

00883

01810

00700

03858

09926

09992

01024

On March 26th at noon, the three major indices of the Hong Kong stock market collectively adjusted, with the Hang Seng Index falling below the 25,000 mark, and the Hang Seng TECH Index experiencing the largest decline. Sector performance was mixed, with individual stocks in life sciences tools and services showing divergent trends, and Jiaxin International Resources plummeting significantly. Popular stocks like Kuaishou and Pop Mart led the market decline, while Xiaomi Group and CNOOC performed strongly, with overall market trading sentiment remaining cautious

- As of noon on March 26, Hong Kong’s three major indices experienced a collective decline, with cautious trading and weak sentiment noted.  
- The Hang Seng Index dropped by 1.37% to 24,988.04, while the Hang Seng Technology Index fell by 2.15% to 4,817.13, both retreating from their March 25 highs.  
- Notable movements included China National Offshore Oil (up 2.39%) and XiaoMi (up 1.54%), while Kuaishou and Alibaba saw significant declines.

Market Heartbeat

CNOOC

XIAOMI-W

TENCENT

JIAXIN INTL RES

AKESO

POP MART

KUAISHOU-W

Hang Seng TECH Index

Hang Seng Index

Hong Kong Stock Midday Review | Hang Seng Index falls 2.15% leading the decline, CNOOC and Xiaomi rise against the trend

159102

01672

513060

512290

159992

Hong Kong's biopharmaceutical sector saw significant stock gains amid market volatility, with XuanZhu Biopharma-Brising over 12%, Ascletis Pharmaincreasing by more than 7%, and both Lepu Biopharmaand XtalPi Holdingsclimbing over 6%. Akeso Biopharmaalso saw a rise of 5.5%. This trend indicates a positive outlook for the biopharmaceutical industry in Hong Kong's stock market.

CoinLive

Huaan Hang Seng Biotech ETF

ASCLETIS-B

Penghua SSE STAR Biology and Medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng Health Care ETF(QDII)

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

LEPU BIO-B

ICBCCS SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

XUANZHUBIO-B

Ping An CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hong Kong Biopharmaceutical Stocks Rise Amid Market Volatility

XTALPI announced its performance for the fiscal year 2025, with revenue of RMB 803 million, an annual increase of 201.2%. It turned a loss into a profit of RMB 124 million, compared to a loss of RMB 1.517 billion in the same period last year; earnings per share were 3 cents. No final dividend will be distributed. During the period, adjusted profit was RMB 258 million, compared to a loss of RMB 457 million in the same period last year

AASTOCKS

"Performance" XTALPI turned a loss into a profit of 124 million RMB for the whole year

XtalPi has appointed Zhou Feiran as its chief financial officer, effective March 10, 2026. Zhou brings experience from J.P. Morgan, where he served as an executive director in global healthcare investment banking. This announcement was published via the Issuer Information Service of the Hong Kong Stock Exchange.

PUBT

XtalPi appoints Zhou Feiran as CFO effective March 10, 2026

The artificial intelligence drug development company XTALPI Co., Ltd. expects a net profit of no less than 100 million yuan last year, turning a profit mainly due to net gains from financial assets of no less than 500 million yuan and revenue growth to 780 million yuan. The company's core business losses have significantly narrowed, and there have been no further fair value losses on convertible redeemable preferred shares. The stock price on Wednesday was HKD 9.44, down 1.05%

BambooWorks

News: Financial asset returns drive XTALPI to turn a profit of at least 100 million last year

09888

09988

During the trading session, the three major indices of the Hong Kong stock market strengthened collectively, with the Hang Seng Index rising by 1.54% and the Hang Seng Tech Index soaring by 3.06%. In terms of sectors, internet content, retail, and hardware sectors led the gains, with leading stocks such as TENCENT, Alibaba, and XIAOMI showing strong performance, significantly boosting market sentiment. Funds are focusing on macro data and policy guidance, with TENCENT temporarily leading in trading volume at HKD 9.82 billion. As of the time of writing, overall trading volume is well-matched, but attention should still be paid to the pressure above

- Hong Kong's market shows a positive trend with the Hang Seng Index up 1.54% to 25,710.46, while the Hang Seng Tech Index and the Enterprise Index also increased.  
- Key sectors include internet content, retail, and hardware, with significant gains from Tencent, Alibaba, and Xiaomi, attracting increased capital.  
- The focus on macroeconomic data such as PMI, retail figures, and external factors like capital flows is influencing market sentiment and investment strategies.

LB Select

BIDU-SW

BABA-W

JD-SW

LENOVO GROUP

GEELY AUTO

MENGNIU DAIRY

KINGSOFT CLOUD

Hong Kong stocks intraday | Three major indices collectively strengthen, with Xiaomi Group and Alibaba leading the gains

Reuters

Xtalpi Holdings Completes HK$2.87 Billion Zero Coupon Convertible Bond Issue

Sunshine Lake Pharma Signs AI Drug R&D Framework with Shenzhen XtalPi

marketscreener

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Hwabao WP CSI Pharmaceuticals ETF

SUNSHINE PHARMA

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Sunshine Lake Pharma Signs AI Drug R&D Framework with Shenzhen XtalPi

03696

02269

02359

02268

INSILICO fell 11.58%; Jingtao Holdings fell 6.23%, with a transaction volume of HKD 792 million; WuXi Biologics fell 3.36%, with a transaction volume of HKD 442 million; WuXi AppTec fell 0.96%, with a transaction volume of HKD 323 million; WuXi Huilian fell 3.71%, with a market value of HKD 83.2 billion

HK Stock Movers Tracker

INSILICO

WUXI BIO

WUXI APPTEC

WUXI XDC

Hong Kong Stock Movement: INSILICO approved by FDA but fell 11.58%, leading stocks in the life sciences sector under pressure

513130

STECH

On January 16th, the three major indices of the Hong Kong stock market experienced slight adjustments, with the Hang Seng Index and the Hang Seng TECH Index retreating slightly, and the previous gains failing to continue. Mainstream sectors showed divergence, with retail and internet leaders exhibiting fluctuating performances. Short-term capital focused on technology and high-tech concepts, with notable gains in popular stocks such as MINIMAX-WP and SYNAGISTICS. The market is highly sensitive to liquidity, macroeconomic recovery, and corporate profit expectations, with an overall moderate risk appetite

- On January 16, Hong Kong stocks showed slight adjustments, with the Hang Seng Index closing at 26,844.96, down 0.29%.  
- Market activity was cautious amid mixed performance in various sectors, particularly in retail and technology, with significant stock movements driven by AI and recent IPO activities.  
- Investors remain focused on economic recovery indicators and corporate earnings amid rising sensitivity to interest rates and liquidity.

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

MNSO

GIGADEVICE

CITIC RESOURCES

SHENGHUI CLEAN

SMIC

MINIMAX-W

SYNAGISTICS

Hong Kong Stock Market Closing | The Hang Seng Index fell 0.29%, with a divergence in the technology and retail sectors, while popular stocks like MINIMAX-WP surged significantly

$XTALPI(02228.HK) looks pretty good. 😄

$XTALPI(2228.HK) is a weird market. The crypto market saw a slight increase, but Hong Kong stocks continued to dive. What kind of trick is the market playing?

$XTALPI(2228.HK) The market is searching for a bottom, hold your positions steady.Fund flow: Large orders outflow 9.78 million, retail investors took over 1.89 million. Institutions are fleeing, retail investors are holding the bag.Hold steady, wait for the wind (opportunity) to come.

Data time: 2026-03-27 10:10 HKT (intraday real-time) $XTALPI(02228.HK) Data source: Longbridge CLI  By Jason 🍎───📊 Current Status Indicator ValueCurrent Price9.43 HKDChange🟢 +1.73%Volume12.98 million sharesTurnover121 million HKD─── 💰 Fund Distribution (As of 10:10 HKT) Order CategoryInflow (10k) Outflow (10k) Net Inflow DirectionLarge Order1,141.88112.48+1,...

📡 2228.HK Fund Flow Analysis

Large orders dominate buying• Large order net inflow 46.31 million, accounting for 84.5% of total net inflow • Medium order net inflow 13.66 million, following the trend • Small order net outflow 5.19 million, retail investors are selling $XTALPI(02228.HK)There are still people exiting. That's good. Mainly because the overall market is too weak. Those willing to give up their ammunition (i.e., sell), just do it. That's all I can say.

[st] ST/HK/2228#XTALPI.HK[/st]The turnover rate is still low.Two possibilities:1. There really is no stock available outside.2. Market makers don't have enough willingness to create FOMO.Let's observe for a few more days.———*For reference only, not investment advice*By Jason 🍎

[st] ST/HK/2228#XTALPI.HK[/st]Held it for a few days, saw money coming in but the price didn't move.The overall market is too weak, let's wait a bit longer.

📡 Capital Radar | $XTALPI(2228.HK) Jingtai Technology【Market】Current price 9.69 HKD (+6.7%), volume 15.58 million shares【Capital Flow】09:34 HKT• Large order net inflow: +13.03 million 🟢• Medium order net inflow: +18.36 million 🟢• Small order net outflow: -0.43 million 🔴【Observations】1. Large and medium orders saw significant synchronized inflows, retail investors did not follow the trend.2. Capital accelerated after market opening, no signs of slowing down.3. Buy order depth is 40 times that of sell orders, strong short-term support.4. Healthy volume-price relationship, good chip lock-up.【Note】No public catalyst for now, continue to monitor the sustainability of capital flows.———*Data source: Longbridge API | For reference only, not investment advice*

$XTALPI(02228.HK) At its current price, I think it's already solid. Where it goes next depends on the market makers, big players, and market sentiment. Hold steady.

📊 Jingtai Holdings (2228.HK) FY2025 Earnings Quick Review Release Date: 2026-03-25 Data Source: HKEX Announcement, Company Report 🔑 Key Highlights Indicator FY2025 YoY Interpretation Revenue ¥803 million +55%+ Rapid growth Net Profit ¥135 million Turned profitable Profit inflection point Net Profit Margin 16.8% - Healthy level 📈 Business Structure Dual-engine drive: - Drug Discovery Solutions: ¥538 million (67%) — Cash cow business - ...

BASF SE

Jingtai Holdings (2228.HK) FY2025 Quick Earnings Review: Revenue +55%, Turns Loss into Profit

SGXTAPI@EC2610A(27177.HK)

SGXTAPI@EC2610A Stock Performance Chart

XTALPI expects revenue of 800 million in 2025: operating profit of 55.24 million, just issued HKD 2.9 billion bonds

The Reality and Illusion of "AI Drug Discovery" XTALPI's Turnaround

Hong Kong Stock Midday Review | Hang Seng Index falls 2.15% leading the decline, CNOOC and Xiaomi rise against the trend

Hong Kong Biopharmaceutical Stocks Rise Amid Market Volatility

"Performance" XTALPI turned a loss into a profit of 124 million RMB for the whole year